Clinical trial

Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC

NCT02497118

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Endostatin Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Vinorelbine Normalized identity: vinorelbineView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-08-01

PhasePHASE4

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

EndostatinDRUG

VinorelbineDRUG · verified · RxNorm: vinorelbine

CisplatinDRUG · verified · RxNorm: cisplatin

Sponsors & collaborators

Tianjin Medical University Cancer Institute and Hospitallead sponsor

Mapped research locations

TianjinTianjin Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02497118 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.